TiGenix Rises On 'Landmark' Phase III Crohn's Data
This article was originally published in Scrip
Executive Summary
Shares in the Belgian biotech firm TiGenix rose by more than 22% to €0.88 on Euronext Brussels on the morning Aug. 24 as it announced "remarkable" top-line Phase III success for its allogeneic cell therapy Cx601 in treating complex perianal fistulas in Crohn's disease patients.